AbCellera reported positive top-line Phase 2 results for ABCL635, an investigational NK3R antagonist antibody being developed for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. In a randomized, double-blind, placebo-controlled multicenter portion enrolling 92 postmenopausal women, ABCL635 met primary endpoints at week 4 after a single 600 mg subcutaneous dose. The company highlighted statistically significant reductions in both frequency and severity of moderate-to-severe hot flashes versus placebo, alongside improvements in sleep and patient global impression of change. AbCellera positioned the dataset as a new efficacy benchmark, with Phase 3 validation framed as the key next milestone. The results continue AbCellera’s broader push into women’s health biologics and add pressure to other non-hormonal options competing for convenience and tolerability differentiation in menopause care. For trial design, the single-dose nature and the week-4 primary readout may influence how future studies structure comparator arms and clinically meaningful effect sizes.